Handbook of Novel Psychoactive Substances (NPS) provides a comprehensive overview of the challenges that clinicians face when dealing with NPS and discusses how the profile of patients and their socio-demographic characteristics frame the serious public health concern that NPS pose. It presents various clinical cases, as well as detailed accounts of symptoms, psychopathology, toxicity, and overall clinical management that NPS require. This handbook brings together a unique collection of chapters written by leading experts in the field, who have felt the need to share their knowledge and experience to improve the clinical practice on NPS and the wellbeing of their patients.
Over the last decade many hundreds of new psychoactive drugs have emerged onto illicit markets. This flood of new drugs has led to clinicians being unsure of the rapidly emerging changing evidence base and uncertain of the best approaches to assessment and clinical management. This book provides a concise, accessible summary of these emerging drugs. By categorizing the hundreds of new drugs by their predominant psychoactive effect - sedative, stimulant and hallucinogenic - the book helps clinicians to manage a drug they are unfamiliar with by using their experience of other drugs with similar psychoactive properties. Written for clinicians from across the frontline, from A&E staff to drug treatment professionals, the authors draw on numerous clinical examples from their own clinical experiences to illustrate aspects of assessment and management. Club drugs and novel psychoactive substances will continue to challenge clinicians and this handbook provides readers with an invaluable introduction to this complex area.
A masterful, high-yield guide to the treatment of substance abuse issues, The ASAM Essentials of Addiction Medicine equips you with the expert know-how you need to provide effective help for your patients. Derived from The ASAM Principles of Addiction Medicine, 5th Edition – widely hailed as the definitive comprehensive clinical reference in the field – this companion resource presents the collective wisdom of hundreds of esteemed authorities on the art and science of addition medicine. Yet, it does so in a succinct format that will appeal to specialists seeking a more streamlined, quick-access reference source. Find the authoritative answers you need on everything from the pharmacology of addiction through diagnosis, assessment, and early intervention; various forms of addiction management...treatment of individual patient populations; management of intoxication and withdrawal; pharmacologic and behavioral interventions; recovery programs; medical disorders and complications...co-occurring addiction and psychiatric disorders; pain and addiction; children and adolescents; and ethical, legal, and liability issues. Contribute to public health in the area of addiction thanks to a special introductory chapter entitled “A Public Health Approach to Prevention: The Health Professional’s Role.” Easily switch back and forth between the ASAM Essentials and the parent text thanks to a parallel chapter organization. Zero in on the most important, practical information thanks to highly focused, efficient coverage. Maximize your understanding and retention of vital concepts with the aid of key points summaries, review questions, and suggested readings in each chapter.
In light of the recent emergence of Novel Psychoactive Substances (NPS) on a global scale, this book provides a timely analysis of the social and economic impact of the NPS phenomenon, and of the global policy and regulatory responses to it. It presents the first comprehensive overview of the international regulation, policy and market structure of the NPS phenomenon, offering a guide to inform legislative discussions and demonstrating from a comparative perspective the different approaches used to address the rise of NPS to date. It covers topics such as organized crime, drug markets, clinical evidence on NPS, and different regulatory approaches also in less explored settings such as prisons and sport environments. Overall, this highly informative and well-structured repository of different experiences with NPS policy, law and regulation offers an essential primary source of evidence for anyone interested in the area of drug and NPS policy, health economics and p ublic health.
This authoritative work comprehensively examines all aspects of addictive disorders and their treatment. Leading researchers and practitioners identify best practices in assessment and diagnosis and provide tools for working with users of specific substances. Issues in working with particular populations--including polysubstance abusers, culturally diverse patients, women, and older adults--are addressed, and widely used psychosocial and pharmacological treatment approaches are reviewed. An indispensable text for anyone studying or treating these prevalent, challenging disorders, the book describes ways to tailor interventions to each patient's needs while delivering compassionate, evidence-based care.
Critical Issues in Alcohol and Drugs of Abuse Testing, Second Edition, addresses the general principles and technological advances for measuring drugs and alcohol, along with the pitfalls of drugs of abuse testing. Many designer drugs, for example, are not routinely tested in drugs of abuse panels and may go undetected in a drug test. This updated edition is a must-have for clinical pathologists, toxicologists, clinicians, and medical review officers and regulators, bridging the gap between technical and clinical information. Topics of note include the monitoring of pain management drugs, bath salts, spices (synthetic marijuana), designer drugs and date rape drugs, and more. - Serves as a ready resource of information for alcohol and drug testing - Ideal resource for making decisions related to the monitoring and interpretation of results - Includes concise content for clinical laboratory scientists, toxicologists and clinicians
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.